Celon Pharma S.A. (WSE:CLN)

Celon Pharma Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	33.64	19.31	26.85	32.36	82.9	147.8
Short-Term Investments	0.9	0.6	48.24	82.18	81.72	79.76
Cash & Short-Term Investments	34.54	19.91	75.09	114.54	164.62	227.55
Cash Growth	-11.41%	-73.49%	-34.45%	-30.42%	-27.65%	417.42%
Accounts Receivable	42.37	41.23	39.26	32.79	27.11	24.67
Other Receivables	20.79	10.94	12.72	15.45	6.59	2.57
Receivables	63.15	52.17	51.99	48.24	33.7	27.25
Inventory	24.11	26.11	30.17	26.41	38.39	23.38
Other Current Assets	3.14	4.08	3.18	0.56	0.87	0.53
Total Current Assets	124.93	102.26	160.43	189.75	237.58	278.7
Property, Plant & Equipment	357.81	303.76	311.66	333.8	341.59	316.57
Long-Term Investments	183.99	6.13	32.69	11.26	13.25	38.12
Other Intangible Assets	25.09	15.69	8.15	14.29	21.15	27.81
Long-Term Deferred Tax Assets	0.02	-	21.55	19.05	28.14	31.94
Long-Term Deferred Charges	-	-	-	0.68	0.68	1.36
Other Long-Term Assets	31.04	18.84	0.22	0.47	0.38	12.64
Total Assets	733.42	457.46	543.8	569.31	642.76	707.14

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	24.47	17.07	15.43	10.51	17.47	11.87
Accrued Expenses	10.56	12.45	8.1	7.39	6.8	3.11
Short-Term Debt	4.37	-	1.53	12.75	-	-
Current Portion of Long-Term Debt	-	1.61	-	-	-	-
Current Portion of Leases	7.41	7.16	7.14	7.13	19.43	6.56
Current Unearned Revenue	0.77	11.83	17.92	31.09	56.42	55.83
Other Current Liabilities	23.31	13.15	16.78	17.48	16.32	8.99
Total Current Liabilities	70.89	63.27	66.9	86.34	116.44	86.36
Long-Term Debt	77.95	1.43	-	-	-	-
Long-Term Leases	38.72	8.74	8.26	5.71	7.39	8.35
Long-Term Unearned Revenue	20.27	19.75	20.22	22.88	25.62	29.85
Long-Term Deferred Tax Liabilities	26.1	-	2.85	3.01	1.32	6.04
Other Long-Term Liabilities	0.93	1.03	0.36	5.81	12.35	22.53
Total Liabilities	234.86	94.21	98.59	123.75	163.12	153.14

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	5.39	5.39	5.39	5.11	5.1	5.1
Additional Paid-In Capital	438.38	516.81	551.25	543.23	587.1	613.51
Retained Earnings	46.46	-159.91	-114.96	-108.64	-119.79	-91.67
Comprehensive Income & Other	8.34	0.96	3.53	5.85	7.23	27.07
Shareholders' Equity	498.57	363.25	445.21	445.56	479.65	554
Total Liabilities & Equity	733.42	457.46	543.8	569.31	642.76	707.14

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	128.44	18.94	16.93	25.59	26.82	14.92
Net Cash (Debt)	-93.91	0.97	58.16	88.95	137.8	212.63
Net Cash Growth	-	-98.34%	-34.62%	-35.45%	-35.19%	1049.56%
Net Cash Per Share	-1.79	0.02	1.08	1.74	2.70	4.55
Filing Date Shares Outstanding	53.86	53.86	53.86	51.06	51.04	51
Total Common Shares Outstanding	53.86	53.86	53.86	51.06	51.04	51
Working Capital	54.04	38.99	93.53	103.41	121.14	192.34
Book Value Per Share	9.26	6.74	8.27	8.73	9.40	10.86
Tangible Book Value	473.47	347.56	437.06	431.26	458.5	526.19
Tangible Book Value Per Share	8.79	6.45	8.12	8.45	8.98	10.32
Land	6.35	-	6.35	6.35	6.35	6.35
Buildings	157.97	-	157.97	146.4	146.35	146.08
Machinery	250.8	-	235.52	272.86	190.43	177.34
Construction In Progress	69.14	-	15.75	79.95	74.3	50.63

Data Source: S&P Global Market Intelligence Last updated: Sep 16, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 25, 2026

Data Sources Report a data error